Biomonitoring in Patients with Preserved Left Ventricular Function after Diagnosed Myocardial Infarction
- Randomized, controlled, parallel-group, open, prospective, multi-center, international study
- To investigate whether the early diagnosis of cardiac arrhythmias, provided by the BIOMONITOR with Home Monitoring, and the consequent treatment of the patient will decrease the risk to experience a major adverse cardiovascular event (MACE) in patients after MI, with LVEF >35% and CHA2DS2-VASc score ≥4 (men) or ≥5 (women)
- 790 patients
Key Result 1
In the primary endpoint analysis of the total patient population, a trend towards MACE reduction in the ICM group was observed but did not reach statistical significance (HR=0.84, p=0.21).
A sub-group analysis shows a 31% reduction of MACE in patients with non-ST segment elevation myocardial infarction (NSTEMI).
Primary endpoint: Time to first major adverse cardiac event (MACE) in NSTEMI and STEMI
MACE reduction with ICM in NSTEMI patients
Key Result 2
The benefit of ICM-guided treatment in NSTEMI patients appears to be connected to their higher risk for primary endpoint events.
increased risk of MACE in NSTEMI patients
Key Result 3
Continuous arrhythmia monitoring in post-MI patients identifies a large arrhythmia burden, and many of the arrhythmias require guideline recommended therapies.
- Arrhythmias are connected to poor outcomes after myocardial infarction.
- BIO|GUARD-MI is the first trial to investigate the impact of continuous arrhythmia monitoring with ICMs on clinical outcomes in post-MI patients.
- Early treatment of high-risk NSTEMI patients guided by continuous arrhythmia monitoring with BIOMONITOR and Home Monitoring may reduce major adverse cardiac events (MACE).
|Main inclusion Criteria||
|Main Exclusion Criteria||